Evidence map›Paper›PMID 41210140›Full record

ReviewFrontiers in psychiatry2025

Everyday stress-induced neurobehavioral dysregulation: therapeutic targets for management with Neurexan.

Stephan Duller, Gerard Clarke, Suzana Herculano-Houzel, Roland von Känel, Peter Kirsch, Hans-Peter Landolt, Britta Naschold, Stefan O Reber, Rudy Schreiber, Martin Walter and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Stephan DullerElementrial Clinical Research, Graz, Austria.
Gerard ClarkeDepartment of Psychiatry and Neurobehavioral Science and APC Microbiome Ireland, University College Cork, Cork, Ireland.
Suzana Herculano-HouzelDepartment of Psychology, Vanderbilt University, Nashville, TN, United States.
Roland von KänelDepartment of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Peter KirschCentral Institute of Mental Health, Mannheim, Germany.
Hans-Peter LandoltInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Britta NascholdHeel GmbH, Baden-Baden, Germany.
Stefan O ReberLaboratory for Molecular Psychosomatics, Department of Psychosomatic Medicine and Psychotherapy, Ulm University Medical Center, Ulm, Germany.
Rudy SchreiberDepartment of Psychopharmacology and Neuropsychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, Netherlands.
Martin WalterDepartment of Psychiatry and Psychotherapy at University Hospital Jena, Jena, Germany.
George M SlavichDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Everyday stress is highly prevalent and can impact human health, performance, well-being, and mortality risk. Despite being widely acknowledged, everyday stress is rarely assessed or treated, highlighting a critical gap in clinical routine. To better understand the relevance of everyday stress for healthcare professionals, we use the Research Domain Criteria (RDoC) framework to link stress neurobiology to its behavioral signs and symptoms. According to RDoC, everyday stress is conceptualized as impacting domains of basic neurobiological functioning. Everyday stress influences two primary domains - the negative valence domain, and arousal and regulatory systems - that can, in turn, lead to mental and physical health problems. Neurexan, a natural multi-component medication, targets these two domains. We review recent data on how Neurexan can mitigate the negative impact of stress on the negative valence domain and regulate arousal, thus helping to restore neurobiological and clinical functioning. This review provides an overview of relevant aspects of stress, mainly everyday stress, and the latest research on Neurexan as a potential option to target everyday stress. More broadly, this work may lead to new methods of assessing and managing everyday stress to improve the psychosocial resilience and well-being of individuals facing difficulty coping with repetitive or chronic stress in their daily lives.

Indexed as

life stressnegative valencepharmacological interventionRDoCtreatment

Identifiers

PMID41210140
PMCPMC12590241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.